Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P07333
UPID:
CSF1R_HUMAN
Alternative names:
CSF-1 receptor; Proto-oncogene c-Fms
Alternative UPACC:
P07333; B5A955; D3DQG2; Q6LDW5; Q6LDY4; Q86VW7
Background:
The Macrophage colony-stimulating factor 1 receptor (CSF-1R), also known as Proto-oncogene c-Fms, plays a pivotal role in the regulation of survival, proliferation, and differentiation of hematopoietic precursor cells. It is crucial for normal bone and tooth development, fertility, and immune responses, acting through pathways like ERK1/2, JNK, and AKT1.
Therapeutic significance:
CSF-1R's involvement in diseases such as Leukoencephalopathy, hereditary diffuse, with spheroids 1, and Brain abnormalities, neurodegeneration, and dysosteosclerosis, underscores its potential as a target for therapeutic intervention in neurodegenerative disorders and bone diseases.